- Home
- EWTX vs MFA Comparison
EWTX vs MFA Comparison
Compare EWTX & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- MFA
- Stock Information
- Founded
- EWTX 2017
- MFA 1997
- Country
- EWTX United States
- MFA United States
- Employees
- EWTX N/A
- MFA N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- MFA Real Estate Investment Trusts
- Sector
- EWTX Health Care
- MFA Real Estate
- Exchange
- EWTX Nasdaq
- MFA Nasdaq
- Market Cap
- EWTX 1.2B
- MFA 1.1B
- IPO Year
- EWTX 2021
- MFA N/A
- Fundamental
- Price
- EWTX $14.70
- MFA $9.46
- Analyst Decision
- EWTX Buy
- MFA Buy
- Analyst Count
- EWTX 8
- MFA 5
- Target Price
- EWTX $40.13
- MFA $13.00
- AVG Volume (30 Days)
- EWTX 1.2M
- MFA 1.7M
- Earning Date
- EWTX 05-08-2025
- MFA 05-06-2025
- Dividend Yield
- EWTX N/A
- MFA 15.22%
- EPS Growth
- EWTX N/A
- MFA N/A
- EPS
- EWTX N/A
- MFA 0.99
- Revenue
- EWTX N/A
- MFA $292,245,000.00
- Revenue This Year
- EWTX N/A
- MFA N/A
- Revenue Next Year
- EWTX N/A
- MFA $7.48
- P/E Ratio
- EWTX N/A
- MFA $9.55
- Revenue Growth
- EWTX N/A
- MFA 52.95
- 52 Week Low
- EWTX $10.60
- MFA $7.85
- 52 Week High
- EWTX $38.12
- MFA $13.45
- Technical
- Relative Strength Index (RSI)
- EWTX 42.22
- MFA 47.31
- Support Level
- EWTX $14.08
- MFA $9.32
- Resistance Level
- EWTX $17.30
- MFA $10.03
- Average True Range (ATR)
- EWTX 1.00
- MFA 0.26
- MACD
- EWTX 0.39
- MFA 0.06
- Stochastic Oscillator
- EWTX 37.50
- MFA 58.70
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company is an internally managed real estate investment trust or REIT.